Petsch, Benjamin

New Vaccine Technologies to Combat Outbreak Situations

Rauch, S., Jasny, E., Schmidt, K. E., & Petsch, B. (2018) · Frontiers in Immunology

SARS-CoV-2 and COVID-19 ResearchImmunotherapy and Immune Responses

Cited by 579

Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection

Petsch, B., Schnee, M., Vogel, A. B., Lange, E., Hoffmann, B., Voss, D., Schlake, T., Thess, A., Kallen, K.-J., Stitz, L., et al. (2012) · Nature Biotechnology

Influenza Virus Research StudiesSARS-CoV-2 and COVID-19 Research

Cited by 464

A novel, disruptive vaccination technology: Self-adjuvanted RNActive ® vaccines

Kallen, K.-J., Heidenreich, R., Schnee, M., Petsch, B., Schlake, T., Thess, A., Baumhof, P., Scheel, B., Koch, S. D., & Fotin-Mleczek, M. (2013) · Human Vaccines & Immunotherapeutics

Immunotherapy and Immune ResponsesRNA Interference and Gene Delivery

Cited by 223

An mRNA Vaccine Encoding Rabies Virus Glycoprotein Induces Protection against Lethal Infection in Mice and Correlates of Protection in Adult and Newborn Pigs

Schnee, M., Vogel, A. B., Voss, D., Petsch, B., Baumhof, P., Kramps, T., & Stitz, L. (2016) · PLOS Neglected Tropical Diseases

Rabies epidemiology and controlVirology and Viral Diseases

Cited by 212

Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response

Edwards, D. K., Jasny, E., Yoon, H., Horscroft, N., Schanen, B., Geter, T., Fotin-Mleczek, M., Petsch, B., & Wittman, V. (2017) · Journal of Translational Medicine

Immunotherapy and Immune ResponsesImmune Response and Inflammation

Cited by 186

mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents

Rauch, S., Roth, N., Schwendt, K., Fotin-Mleczek, M., Mueller, S. O., & Petsch, B. (2021) · npj Vaccines

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 165

Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine

Gebre, M. S., Rauch, S., Roth, N., Yu, J., Chandrashekar, A., Mercado, N. B., He, X., Liu, J., McMahan, K., Martinot, A., et al. (2022) · Nature

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 127

A thermostable messenger RNA based vaccine against rabies

Stitz, L., Vogel, A., Schnee, M., Voss, D., Rauch, S., Mutzke, T., Ketterer, T., Kramps, T., & Petsch, B. (2017) · PLOS Neglected Tropical Diseases

Rabies epidemiology and controlRNA Interference and Gene Delivery

Cited by 117

Advances in RNA vaccines for preventive indications: A case study of a vaccine against rabies

Armbruster, N., Jasny, E., & Petsch, B. (2019) · Vaccines

Rabies epidemiology and controlRNA Interference and Gene Delivery

Cited by 95

mRNA vaccine CVnCoV protects non-human primates from SARS-CoV-2 challenge infection

Rauch, S., Gooch, K., Hall, Y., Salguero, F. J., Dennis, M. J., Gleeson, F. V., Harris, D., Ho, C., Humphries, H. E., Longet, S., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory)

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 48

CVnCoV protects human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2

Hoffmann, D., Corleis, B., Rauch, S., Roth, N., Mühe, J., Halwe, N. J., Ulrich, L., Fricke, C., Schön, J., Kraft, A., et al. (2021) · Nature Communications

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 48

Efficacy of an unmodified bivalent mRNA vaccine against SARS-CoV-2 variants in female small animal models

Corleis, B., Hoffmann, D., Rauch, S., Fricke, C., Roth, N., Gergen, J., Kovacikova, K., Schlottau, K., Halwe, N. J., Ulrich, L., et al. (2023) · Nature Communications

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 22

Optimised Non-Coding Regions of mRNA SARS-CoV-2 Vaccine CV2CoV Improves Homologous and Heterologous Neutralising Antibody Responses

Roth, N., Schön, J., Hoffmann, D., Thran, M., Thess, A., Mueller, S. O., Petsch, B., & Rauch, S. (2022) · Vaccines

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 22

Optimised non-coding regions of mRNA SARS-CoV-2 vaccine CV2CoV improves homogeneous and heterogenous neutralising antibody responses

Roth, N., Schön, J., Hoffmann, D., Thran, M., Thess, A., Mueller, S. O., Petsch, B., & Rauch, S. (2021) · bioRxiv (Cold Spring Harbor Laboratory)

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 18

Optimization of Non-Coding Regions Improves Protective Efficacy of an mRNA SARS-CoV-2 Vaccine in Nonhuman Primates

Gebre, M. S., Rauch, S., Roth, N., Yu, J., Chandrashekar, A., Mercado, N. B., He, X., Liu, J., McMahan, K., Martinot, A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory)

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 8